Compare CRMD & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMD | PRTC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.9M | 464.3M |
| IPO Year | 2009 | N/A |
| Metric | CRMD | PRTC |
|---|---|---|
| Price | $6.61 | $15.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 3.8K |
| Earning Date | 03-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.17 | $8.09 |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $5.60 | $13.30 |
| 52 Week High | $17.43 | $20.00 |
| Indicator | CRMD | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 38.23 |
| Support Level | $6.55 | $15.60 |
| Resistance Level | $7.44 | $18.10 |
| Average True Range (ATR) | 0.24 | 0.48 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 58.83 | 9.13 |
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.